Skip Nav Destination
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants
Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?
Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin
Platelet-associated CD154 in immune thrombocytopenic purpura
Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment
Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses
Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)
Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial
Alpha phenyl-tert-butyl nitrone (PBN) protects syngeneic marrow transplant recipients from the lethal cytokine syndrome occurring after agonistic CD40 antibody administration
Issue Archive
January 1 2005
Table of Contents
INSIDE BLOOD
BLOOD WORK
REVIEW ARTICLES
ERRATA
REVIEW IN TRANSLATIONAL HEMATOLOGY
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
Clinical Trials & Observations
CHEMOKINES
Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient
Marcin Wysoczynski,Ryan Reca,Janina Ratajczak,Magda Kucia,Neeta Shirvaikar,Marek Honczarenko,Michael Mills,Jens Wanzeck,Anna Janowska-Wieczorek,Mariusz Z. Ratajczak
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
Clinical Trials & Observations
John C. Byrd,Kanti Rai,Bercedis L. Peterson,Frederick R. Appelbaum,Vicki A. Morrison,Jonathan E. Kolitz,Lois Shepherd,John D. Hines,Charles A. Schiffer,Richard A. Larson
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
Clinical Trials & Observations
Richard M. Stone,Daniel J. DeAngelo,Virginia Klimek,Ilene Galinsky,Eli Estey,Stephen D. Nimer,Wilson Grandin,David Lebwohl,Yanfeng Wang,Pamela Cohen,Edward A. Fox,Donna Neuberg,Jennifer Clark,D. Gary Gilliland,James D. Griffin
Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants
Clinical Trials & Observations
Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?
Clinical Trials & Observations
Brief Report
David Saadoun,Felipe Suarez,François Lefrere,Françoise Valensi,Xavier Mariette,Achille Aouba,Caroline Besson,Bruno Varet,Xavier Troussard,Patrice Cacoub,Oliver Hermine
HEMATOPOIESIS
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Nongenomic effects of 17β-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor β and Src kinase
Laura Moro,Stefania Reineri,Daniela Piranda,Daniela Pietrapiana,Paolo Lova,Alessandra Bertoni,Andrea Graziani,Paola Defilippi,Ilaria Canobbio,Mauro Torti,Fabiola Sinigaglia
Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin
Clinical Trials & Observations
Pierre Savi,Beng H. Chong,Andreas Greinacher,Yves Gruel,John G. Kelton,Theodore E. Warkentin,Petra Eichler,Dick Meuleman,Maurice Petitou,Jean-Pascal Herault,Roger Cariou,Jean-Marc Herbert
Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction
Margherita Massa,Vittorio Rosti,Maurizio Ferrario,Rita Campanelli,Isabella Ramajoli,Roberta Rosso,Gaetano M. De Ferrari,Marco Ferlini,Lucio Goffredo,Alessandra Bertoletti,Catherine Klersy,Alessandro Pecci,Remigio Moratti,Luigi Tavazzi
Platelet-associated CD154 in immune thrombocytopenic purpura
Brief Report
Anne Solanilla,Jean-Max Pasquet,Jean-François Viallard,Cécile Contin,Christophe Grosset,Julie Déchanet-Merville,Maryse Dupouy,Marc Landry,Francis Belloc,Paquita Nurden,Patrick Blanco,Jean-François Moreau,Jean-Luc Pellegrin,Alan T. Nurden,Jean Ripoche
IMMUNOBIOLOGY
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells
Ennio Carbone,Paola Neri,Maria Mesuraca,Mariateresa T. Fulciniti,Takemi Otsuki,Daniela Pende,Veronika Groh,Thomas Spies,Giuditta Pollio,David Cosman,Lucio Catalano,Pierfrancesco Tassone,Bruno Rotoli,Salvatore Venuta
NEOPLASIA
Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment
Clinical Trials & Observations
Annuska M. Glas,Marie José Kersten,Leonie J. M. J. Delahaye,Anke T. Witteveen,Robby E. Kibbelaar,Arno Velds,Lodewyk F. A. Wessels,Peter Joosten,Ron M. Kerkhoven,René Bernards,Johan H. J. M. van Krieken,Philip M. Kluin,Laura J. van't Veer,Daphne de Jong
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis
Steffen Koschmieder,Berthold Göttgens,Pu Zhang,Junko Iwasaki-Arai,Koichi Akashi,Jeffery L. Kutok,Tajhal Dayaram,Kristin Geary,Anthony R. Green,Daniel G. Tenen,Claudia S. Huettner
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)
Thomas Kindler,Frank Breitenbuecher,Stefan Kasper,Eli Estey,Francis Giles,Eric Feldman,Gerhard Ehninger,Gary Schiller,Virginia Klimek,Stephen D. Nimer,Alois Gratwohl,Chuna Ram Choudhary,Constan Mueller-Tidow,Hubert Serve,Harald Gschaidmeier,Pamela S. Cohen,Christoph Huber,Thomas Fischer
RED CELLS
TRANSPLANTATION
Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses
Clinical Trials & Observations
Donald W. Milligan,Savio Fernandes,Ranjit Dasgupta,Faith E. Davies,Estella Matutes,Christopher D. Fegan,Christopher McConkey,J. Anthony Child,David Cunningham,Gareth J. Morgan,Daniel Catovsky,for the National Cancer Research Institute (NCRI) Haematological Studies Group
Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)
Clinical Trials & Observations
Laurent Garderet,Myriam Labopin,Norbert-Claude Gorin,Emmanuelle Polge,André Baruchel,Giovanna Meloni,Juan Ortega,Jaak Vossen,Donald Bunjes,Guy Leverger,Didier Blaise,Augustin Ferrant,Mats Brune,Eric Dore,Helmut Gadner,Felix Zintl,Isaac Yaniv,Giorgio Dini,Francesco Frassoni
Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial
Clinical Trials & Observations
Franco Locatelli,Peter Nöllke,Marco Zecca,Elisabeth Korthof,Edoardo Lanino,Christina Peters,Andrea Pession,Hartmut Kabisch,Cornelio Uderzo,Carmen S. Bonfim,Peter Bader,Dagmar Dilloo,Jan Stary,Alexandra Fischer,Tom Révész,Monika Führer,Henrik Hasle,Monika Trebo,Marry M. van den Heuvel-Eibrink,Susanna Fenu,Brigitte Strahm,Giovanna Giorgiani,Mario Regazzi Bonora,Ulrich Duffner,Charlotte M. Niemeyer,on behalf of the European Working Group on Childhood MDS (EWOG-MDS) and the European Blood and Marrow Transplantation (EBMT) Group
Alpha phenyl-tert-butyl nitrone (PBN) protects syngeneic marrow transplant recipients from the lethal cytokine syndrome occurring after agonistic CD40 antibody administration
Brief Report
Maria Gendelman,Nadine Halligan,Richard Komorowski,Brent Logan,William J. Murphy,Bruce R. Blazar,Kirkwood A. Pritchard, Jr,William R. Drobyski
CORRESPONDENCE
-
Cover Image
Cover Image
Advertisement
Email alerts
Advertisement